Seaport Therapeutics set terms for a $201 million initial public offering expected to price this week, bringing its neuropsychiatric pipeline to public markets at a moment when psychopharmacology assets are drawing capital after a three-year drought. The Boston-based company plans to offer 11.5 million shares at $16 to $18 per share, according to regulatory filings Wednesday.

The company's lead asset, SPT-104, is a Phase 3-ready candidate targeting major depressive disorder with a differentiated mechanism—selective κ-opioid receptor antagonism. Seaport has dosed 370 patients across five clinical trials and expects to initiate two pivotal Phase 3 studies in Q2 2025. The IPO proceeds will fund those trials through data readouts expected in 2027, with additional capital allocated to STP-200 series programs addressing insomnia and panic disorder. The company's pre-money valuation sits at approximately $930 million at the midpoint, a 2.1x multiple on trailing private funding rounds from 2023.

The timing matters because psychopharmacology has returned to institutional favor after a prolonged period of skepticism. Failed MDMA and ketamine programs cost allocators $8 billion in destroyed equity value between 2021 and 2023, creating an overhang that suppressed sector multiples. But three FDA approvals in late 2024—including Axsome's AXS-07 for migraine and Biohaven's Kv7 modulator for anxiety—reset the risk curve. Mental health targets now carry lower clinical failure discounts, and Seaport enters with a mechanism that circumvents serotonergic pathways crowded by generic SSRIs. The κ-opioid angle also offers cleaner regulatory optics than psychedelic-adjacent molecules that still face DEA scheduling friction.

Seaport's structure suggests the company is pricing for committed biotech allocators, not crossover tourists. The deal size sits below the $250 million threshold that typically attracts large-cap health care funds, and the valuation assumes success probabilities higher than sector averages—Phase 3 depression trials historically succeed at 52% rates, yet Seaport is trading at a premium to Phase 2 peers. That spread implies the underwriters—Goldman Sachs, Leerink Partners, and Guggenheim Securities—have pre-sold a meaningful portion of the book to accounts that already know the κ-opioid literature and are willing to pay for late-stage positioning.

Watch for allocation data in the final prospectus, expected Thursday evening. If insider lockup terms extend beyond the standard 180 days, that signals underwriter confidence in sustained post-IPO demand. Seaport's management has not disclosed whether it will reserve shares for strategic pharmaceutical partners, but the depression market—worth $16 billion annually in the U.S. alone—makes the company an acquisition candidate if Phase 3 data meet endpoints. Precedent transactions value late-stage CNS assets at $1.2 billion to $2.8 billion, depending on patient population size and existing competitive therapies.

The first trading session will clarify whether the neuropsychiatric rebound has institutional legs or remains confined to specialist funds. Seaport priced conservatively, leaving 18% to 22% first-day upside at the midpoint—a structure that favors stability over pop. That discipline will show in how the stock trades through the 30-day quiet period, when early data on patient enrollment velocity becomes available.